Difference between revisions of "Talk:Assessment of the health impacts of H1N1 vaccination/Group D"
Carmen Gil (talk | contribs) (→Pandemrix should not be used because of narcolepsy risk) |
m |
||
| Line 21: | Line 21: | ||
*[http://www.rokotusinfo.fi/rokotteet/sikainfluenssa_html] | *[http://www.rokotusinfo.fi/rokotteet/sikainfluenssa_html] | ||
*[http://www.ktl.fi/portal/suomi/osastot/vimo/tutkimus-_ja_seurantakohteet/influenssa/influenssan_seuranta/#navi0] | *[http://www.ktl.fi/portal/suomi/osastot/vimo/tutkimus-_ja_seurantakohteet/influenssa/influenssan_seuranta/#navi0] | ||
| + | |||
| + | |||
| + | {{comment|# |JUNE: I have your notebook.|--[[User:Jouni|Jouni]] 11:50, 1 April 2011 (EEST)}} | ||
Revision as of 08:50, 1 April 2011
Pandemrix should not be used because of narcolepsy risk
| Statements: Pandemrix should not be used any more anywhere because its narcolepsy risk is too high. NOTE! The time of the statement is September 2010.
Resolution: Resolution not yet found. (A stable resolution, when found, should be updated to the main page.) |
| Argumentation:
⇤1 : Despite risks, Pandemrix is an effective vaccine and has clearly net positive effects in countries where emergency treatment is poorly available for severe swine flu cases. --Jouni 23:05, 31 March 2011 (EEST)
--# : The decision to use Pandemrix was probably led by panic and other choices should be considered at this point --Carmen Gil 11:25, 1 April 2011 (EEST)
←2 : The reputation of Pandemrix is globally so poor that it is impossible to use it any more. --Jouni 23:05, 31 March 2011 (EEST) ←3 : In Finland, THL decided to stop the use of Pandemrix. --Jouni 23:05, 31 March 2011 (EEST), [1] ⇤# : Pandemrix has a lower Hg content than other vaccines (2.5 vs 25 µg), which could cause other neurological problems in children --Carmen Gil 11:25, 1 April 2011 (EEST) |
--# : JUNE: I have your notebook. --Jouni 11:50, 1 April 2011 (EEST)
